Smoking: a Risk Factor for Pulmonary Arterial Hypertension?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Environmental factors may play a role in the genesis of pulmonary hypertension, especially in endothelial dysfunction. One widespread environmental factor associated with systemic endothelial dysfunction is cigarette smoke. It may well be that cigarette smoking is not only a risk factor for systemic but also for pulmonary vascular diseases and herewith may interact with other risk factors such as a genetic background and associated conditions. The existing studies which deal with this subject are only small single center case control studies providing less data. Therefore a large European multicenter study is necessary.

The investigators hypothesis are:

* a history of tobacco smoke exposure is highly prevalent in patients with PAH compared to the unaffected general population.
* a history of tobacco smoke exposure is more prevalent in patients with PAH compared to CTEPH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hemodynamic Changes in Connective Tissue Disease

NCT01468792

Systemic Sclerosis

COMPLETED

A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects

NCT00848406

Asthma Copd

COMPLETED

Exercise Hemodynamics in Patients With Pulmonary Fibrosis

NCT03706820

Exercise Pulmonary Hypertension

UNKNOWN

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

NCT01730092

Pulmonary Disease Pulmonary Hypertension

RECRUITING

Endothelial Dysfunction in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

NCT01460082

Chronic Obstructive Pulmonary Disease (COPD) Inflammatory Disease Endothelial Dysfunction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PAH

Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure \>25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg

No interventions assigned to this group

CTEPH

Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure \>25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.

No interventions assigned to this group

Controll group

Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.

No interventions assigned to this group